

# Anteris Technologies Ltd

15:11 22 Nov 2017

## Admedus receives approval to sell CardioCel in India

Admedus Ltd (ASX:AHZ) has received regulatory approval to launch the company's flagship CardioCel® product in the Republic of India.

This approval allows for the immediate commercial sale of CardioCel in India, a healthcare market worth \$158 billion and growing rapidly.

CardioCel is the company's flagship product and is becoming a surgeon-preferred biomaterial for heart valve repair surgeries.

Admedus has appointed Syncronai Medical India Pvt Ltd as its exclusive commercial partner managing all sales, marketing and distribution.

### Wayne Paterson, chief executive, said

"We are excited to partner with Syncronai Medical to offer Indian hospitals and surgeons our clinically superior ADAPT® technology with CardioCel.

"This is a clinically meaningful offering for them and a significant long-term opportunity for Admedus."

### A market with a need for CardioCel

India has circa 50 million cardiac patients.

Heart problems continue to be a challenge for the Indian healthcare system with 280,000 babies being born annually with a congenital heart defect.

### The Indian market is a growth opportunity

The regulatory approval is a result positive pre-market research to determine the demand for CardioCel.

Results showed strong interest from Indian key opinion leaders who are eager to start using CardioCel as soon as possible.

Furthermore, pre-market assessment for VasculCel® and CardioCel 3D is now in the final stages.

During 2018, Admedus plans to move up the value chain with the entire platform of ADAPT products in the large Indian market.

### An emerging healthcare company

Admedus has two key revenue streams which totalled \$22.3 million in FY17.

These include ADAPT®, the company's clinically superior regenerative tissue technology.

**Price:** 4.08

**Market Cap:** \$24.11 m

#### 1 Year Share Price Graph



#### Share Information

**Code:** AVR

**Listing:** ASX

<b>52 week</b>	<b>High</b>	<b>Low</b>
	7.5	3.03

**Sector:** Pharma & Biotech

**Website:** anteristech.com

#### Company Synopsis:

*Anteris Technologies Ltd (ASX:AVR) is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients.*

action@proactiveinvestors.com

Sales for the ADAPT® portfolio of products for the period climbed 30% to \$6.9 million

The second is the company's infusion business in Australia and New Zealand, where revenue increased 74% to \$15.5 million.

**READ: Admedus secures debt funding to expand business**

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).